correct me if I'm wrong but during the AMA conference back in Nov 2019 Hikma made a presentation that shocked everyone with there forecast of a generic vascepa of somewhere in the neighborhood of $750 mill annual revs
It wasn't their forecast. I don't want to misspeak and say what it was, but it wasn't their forecast.